Brokers Issue Forecasts for PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a report issued on Monday, October 28th. William Blair analyst B. Vazquez expects that the company will post earnings of ($0.19) per share for the quarter. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.88) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q2 2026 earnings at $0.20 EPS and Q3 2026 earnings at $0.16 EPS.

Several other brokerages have also recently weighed in on PRCT. Wells Fargo & Company boosted their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Piper Sandler restated an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. TD Cowen upped their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a report on Monday, September 16th. Bank of America upped their price objective on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Truist Financial upped their price objective on PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of “Buy” and a consensus price target of $86.40.

PROCEPT BioRobotics Trading Up 6.3 %

PRCT stock opened at $96.69 on Wednesday. The company has a current ratio of 7.51, a quick ratio of 6.49 and a debt-to-equity ratio of 0.20. PROCEPT BioRobotics has a 12-month low of $24.83 and a 12-month high of $97.15. The stock has a market cap of $5.02 billion, a price-to-earnings ratio of -46.94 and a beta of 1.03. The business’s 50-day moving average is $76.37 and its 200 day moving average is $67.41.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. The company had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $53.30 million. During the same period in the previous year, the firm posted ($0.51) EPS. PROCEPT BioRobotics’s revenue was up 66.4% compared to the same quarter last year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC increased its holdings in PROCEPT BioRobotics by 0.3% in the third quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company’s stock valued at $6,489,000 after buying an additional 228 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of PROCEPT BioRobotics during the third quarter worth about $27,000. Arizona State Retirement System grew its holdings in shares of PROCEPT BioRobotics by 2.8% during the second quarter. Arizona State Retirement System now owns 12,840 shares of the company’s stock worth $784,000 after purchasing an additional 350 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of PROCEPT BioRobotics by 4.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company’s stock worth $606,000 after purchasing an additional 408 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of PROCEPT BioRobotics by 11.7% during the third quarter. Blue Trust Inc. now owns 4,441 shares of the company’s stock worth $356,000 after purchasing an additional 466 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai sold 35,220 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the sale, the director now owns 23,963 shares of the company’s stock, valued at approximately $1,824,063.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Kevin Waters sold 25,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total value of $1,811,750.00. Following the transaction, the chief financial officer now owns 96,096 shares of the company’s stock, valued at $6,964,077.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Antal Rohit Desai sold 35,220 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total value of $2,680,946.40. Following the completion of the transaction, the director now directly owns 23,963 shares in the company, valued at $1,824,063.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 179,892 shares of company stock valued at $13,946,415 over the last quarter. 17.40% of the stock is owned by company insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).